Oxford BioDynamics
Financials
Estimates*
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.0m | 1.0m | - | <1m | <1m | <1m | <1m |
| % growth | 20 % | - | - | - | (25 %) | (55 %) | 231 % |
| EBITDA | (2.0m) | (2.0m) | (3.0m) | (4.4m) | (6.4m) | (7.3m) | (8.7m) |
| % EBITDA margin | (200 %) | (200 %) | - | (957 %) | (1875 %) | (4710 %) | (1707 %) |
| Profit | (3.0m) | (1.0m) | (2.0m) | (4.3m) | (6.7m) | (6.7m) | (10.8m) |
| % profit margin | (300 %) | (100 %) | - | (946 %) | (1960 %) | (4357 %) | (2123 %) |
| EV / revenue | 156.9x | 179.7x | - | 183.0x | 126.7x | 108.3x | 149.1x |
| EV / EBITDA | -78.5x | -89.8x | -22.5x | -19.1x | -6.8x | -2.3x | -8.7x |
| R&D budget | - | - | - | - | <1m | <1m | <1m |
| R&D % of revenue | - | - | - | - | 263 % | 342 % | 149 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
| N/A | N/A | IPO | |
* | $12.5m | Post IPO Equity | |
N/A | Grant | ||
* | N/A | £9.1m | Post IPO Equity |
* | N/A | £5.6m | Post IPO Equity |
* | N/A | £9.9m Valuation: £19.0m 37.3x EV/LTM Revenues -2.2x EV/LTM EBITDA | Post IPO Equity |
| Total Funding | - | ||
Related Content
Recent News about Oxford BioDynamics
EditOxford BioDynamics Plc is a biotechnology company specializing in the development of epigenetic biomarkers using its proprietary EpiSwitch™ platform. The company operates in the personalized medicine market, focusing on early detection and stratification of diseases such as neurodegenerative disorders and cancer. Its clients include pharmaceutical companies, healthcare providers, and research institutions in the US, Europe, and Asia. The business model revolves around providing biomarker discovery services and licensing its technology to partners. Revenue is generated through service fees, licensing agreements, and collaborative research projects.
Keywords: epigenetics, biomarkers, personalized medicine, EpiSwitch™, neurodegenerative diseases, cancer, pharmaceutical, healthcare, biotechnology, diagnostics.
